ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Authorization Legislation Still On Congress Busy Agenda, Along With Risk Assessment, Appropriations

February 3, 1984

Senate Bill Would Prohibit Political Appointments To Advisory Groups

January 9, 1976

Afinitor Extends PFS In Women With EGFR-2 Positive Disease

June 28, 2013

Isis 3521 Gets Fast-track Status For FDA Review.

December 1, 2000

Applications Pour In for construction Grants; Three Compete For Mouse Laboratory

June 1, 1990

House Appropriations Adds $20 Mil. To Bush Request For NCI, Emphasizes Three Cancers

June 28, 1991